Aligos Therapeutics (ALGS) Depreciation and Depletion (2021 - 2025)
Aligos Therapeutics filings provide 5 years of Depreciation and Depletion readings, the most recent being $257000.0 for Q4 2025.
- On a quarterly basis, Depreciation and Depletion rose 13.22% to $257000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $951000.0, a 15.62% decrease, with the full-year FY2025 number at $930000.0, down 9.44% from a year prior.
- Depreciation and Depletion hit $257000.0 in Q4 2025 for Aligos Therapeutics, up from $200000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $800000.0 in Q2 2021 to a low of $194000.0 in Q1 2025.
- Median Depreciation and Depletion over the past 5 years was $417500.0 (2023), compared with a mean of $453950.0.
- Biggest five-year swings in Depreciation and Depletion: plummeted 47.82% in 2024 and later increased 13.22% in 2025.
- Aligos Therapeutics' Depreciation and Depletion stood at $709000.0 in 2021, then fell by 27.22% to $516000.0 in 2022, then dropped by 15.7% to $435000.0 in 2023, then plummeted by 47.82% to $227000.0 in 2024, then grew by 13.22% to $257000.0 in 2025.
- The last three reported values for Depreciation and Depletion were $257000.0 (Q4 2025), $200000.0 (Q3 2025), and $300000.0 (Q2 2025) per Business Quant data.